pentacyano(isoniazid)ferrate(II)

an antitubercular agent that inhibits enoyl-acyl carrier protein reductase

Also Known As:

IQG-607

Networked: 8 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Inorganic Chemicals: 9
- Iron Compounds: 87
  - Ferrous Compounds: 2
    - pentacyano(isoniazid)ferrate(II): 8
Organic Chemicals: 133
- Hydrazines: 379
  - Isoniazid: 7614
    - pentacyano(isoniazid)ferrate(II): 8
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Isonicotinic Acids: 144
      - Isoniazid: 7614
        pentacyano(isoniazid)ferrate(II): 8
- Heterocyclic Acids
  - Isonicotinic Acids: 144
    - Isoniazid: 7614
      - pentacyano(isoniazid)ferrate(II): 8

Experts

1.	Rodrigues-Junior, Valnês S: 6 articles (03/2020 - 08/2012)
2.	Basso, Luiz A: 5 articles (03/2020 - 01/2014)
3.	Machado, Pablo: 5 articles (03/2020 - 11/2017)
4.	Bizarro, Cristiano V: 4 articles (03/2020 - 01/2018)
5.	Villela, Anne D: 4 articles (03/2020 - 01/2014)
6.	Campos, Maria M: 4 articles (01/2018 - 08/2012)
7.	Abbadi, Bruno L: 3 articles (03/2020 - 01/2018)
8.	Pissinate, Kenia: 3 articles (03/2020 - 01/2018)
9.	Santos, Diógenes S: 3 articles (01/2018 - 01/2014)
10.	Sperotto, Nathalia D M: 2 articles (03/2020 - 01/2018)

Related Diseases

1.	Tuberculosis (Tuberculoses) 01/01/2018 - "Further efforts are suggested to be pursued toward attempting to translate IQG-607 into a chemotherapeutic agent to treat tuberculosis." 01/01/2018 - "Preclinical pharmacokinetic profiling of IQG-607, a potential oral metallodrug to treat tuberculosis." 01/01/2014 - "Importantly, treatment of M.-tuberculosis-infected macrophages with IQG-607 significantly diminished the number of CFU compared with the untreated control group. " 01/01/2014 - "In this work, the antitubercular activity of a pentacyano(isoniazid)ferrate(II) compound (IQG-607) was investigated using a macrophage model of Mycobacterium tuberculosis infection. " 08/01/2012 - "Activity of IQG-607, a new orally active compound, in a murine model of Mycobacterium tuberculosis infection."
2.	Infections 01/01/2018 - "MIC measurements and macrophage infection experiments with a laboratorial strain showed that katG mutation is sufficient to confer resistance to IQG-607 and that the macrophage intracellular environment cannot trigger the self-activation mechanism. " 01/01/2018 - "Experiments using early and late controls of infection revealed a bactericidal activity for IQG-607. " 08/01/2012 - "Experiments using early and late controls of infection revealed a bactericidal activity for IQG-607. " 03/01/2020 - "IQG-607 is an orally active anti-tuberculosis drug candidate, with promising preliminary safety profile and anti-mycobacterial activity in both in vitro and in vivo models of tuberculosis infection. " 11/01/2017 - "IQG-607 is an anti-tuberculosis drug candidate, with a promising safety and efficacy profile in models of tuberculosis infection both in vitro and in vivo. "
3.	Diarrhea 11/01/2017 - "Diarrhea and alopecia were the clinical signs observed in animals dosed with IQG-607 for 90 days. "
4.	Alopecia (Baldness) 11/01/2017 - "Diarrhea and alopecia were the clinical signs observed in animals dosed with IQG-607 for 90 days. "

Related Drugs and Biologics

1.	Isoniazid (Ftivazide)
2.	Antitubercular Agents
3.	Triclosan (pHisoHex)
4.	Metals
5.	Ethionamide (Trecator-SC)
6.	pentacyano(2- methyl- 5- (pyridin- 4- yl)- 1,3,4- oxadiazole)ferrate(II)

Related Therapies and Procedures

1.	Combination Drug Therapy (Combination Chemotherapy)